US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4740461A
(en)
|
1983-12-27 |
1988-04-26 |
Genetics Institute, Inc. |
Vectors and methods for transformation of eucaryotic cells
|
EP0154316B1
(fr)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Lymphokine chimiquement modifiée et son procédé de préparation
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
CA1319120C
(fr)
|
1985-04-01 |
1993-06-15 |
John Henry Kenten |
Lignee cellulaire myelomateuse transformee et expression d'un gene codant pour un polypeptide d'eucaryote a l'aide de cette lignee
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
US4959455A
(en)
|
1986-07-14 |
1990-09-25 |
Genetics Institute, Inc. |
Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
DE3785186T2
(de)
|
1986-09-02 |
1993-07-15 |
Enzon Lab Inc |
Bindungsmolekuele mit einzelpolypeptidkette.
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
US4912040A
(en)
|
1986-11-14 |
1990-03-27 |
Genetics Institute, Inc. |
Eucaryotic expression system
|
EP0307434B2
(fr)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Anticorps alteres
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
US5229289A
(en)
|
1988-03-11 |
1993-07-20 |
The Biomembrane Institute |
Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
|
JP2989002B2
(ja)
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
化学修飾顆粒球コロニー刺激因子
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
US5420245A
(en)
|
1990-04-18 |
1995-05-30 |
Board Of Regents, The University Of Texas |
Tetrapeptide-based inhibitors of farnesyl transferase
|
DE69232137T2
(de)
|
1991-11-25 |
2002-05-29 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US6129914A
(en)
|
1992-03-27 |
2000-10-10 |
Protein Design Labs, Inc. |
Bispecific antibody effective to treat B-cell lymphoma and cell line
|
CA2118508A1
(fr)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Production par recombinaison genetique de domaines semblables aux immunoglobulines dans les cellules procaryotes
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
CA2111902A1
(fr)
|
1992-12-21 |
1994-06-22 |
Jack Beuford Campbell |
Compositions antitumorales et methodes therapeutiques
|
WO1994019357A1
(fr)
|
1993-02-23 |
1994-09-01 |
Merrell Dow Pharmaceuticals Inc. |
Inhibiteurs de la transferase farnesyl:proteine utiles comme agents anticancereux
|
CA2118985A1
(fr)
|
1993-04-02 |
1994-10-03 |
Dinesh V. Patel |
Inhibiteurs heterocycliques de la farnesyl proteine transferase
|
JPH09500615A
(ja)
|
1993-05-14 |
1997-01-21 |
ジェネンテク,インコーポレイテッド |
Ras−ファルネシル転移酵素阻害剤
|
US5602098A
(en)
|
1993-05-18 |
1997-02-11 |
University Of Pittsburgh |
Inhibition of farnesyltransferase
|
CA2163345A1
(fr)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Anticorps
|
US5728830A
(en)
|
1993-09-22 |
1998-03-17 |
Kyowa Hakko Kogyo Co., Ltd. |
Farnesyltransferase inhibitor
|
US5721236A
(en)
|
1993-10-15 |
1998-02-24 |
Schering Corporation |
Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
|
CA2174105C
(fr)
|
1993-10-15 |
2002-02-12 |
W. Robert Bishop |
Composes carbamates tricycliques servant a inhiber la fonction de la proteine g et au traitement de maladies proliferatives
|
US5661152A
(en)
|
1993-10-15 |
1997-08-26 |
Schering Corporation |
Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
|
ES2164717T3
(es)
|
1993-10-15 |
2002-03-01 |
Schering Corp |
Compuestos triciclicos de sulfonamida utiles para inhibir la funcion de la proteina-g y para el tratamiento de enfermedades proliferativas.
|
IL111235A
(en)
|
1993-10-15 |
2001-03-19 |
Schering Plough Corp |
Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
|
US5719148A
(en)
|
1993-10-15 |
1998-02-17 |
Schering Corporation |
Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
|
ATE200677T1
(de)
|
1993-10-25 |
2001-05-15 |
Parke Davis & Co |
Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
|
JPH08505646A
(ja)
|
1993-11-04 |
1996-06-18 |
アボツト・ラボラトリーズ |
スクアレンシンテターゼ及びプロテインファルネシルトランスフェラーゼのインヒビターとしてのシクロブタン誘導体
|
US5783593A
(en)
|
1993-11-04 |
1998-07-21 |
Abbott Laboratories |
Inhibitors of squalene synthetase and protein farnesyltransferase
|
HUT75308A
(en)
|
1993-11-05 |
1997-05-28 |
Warner Lambert Co |
Substituted di- and tripeptide inhibitors of protein:farnesyl transferase
|
US5484799A
(en)
|
1993-12-09 |
1996-01-16 |
Abbott Laboratories |
Antifungal dorrigocin derivatives
|
WO1995024612A1
(fr)
|
1994-03-07 |
1995-09-14 |
International Business Machines Corporation |
Procede et dispositif d'interpolation rapide de valeurs intermediaires derivees de signaux periodiques dephases et de detection de defauts de corps rotatifs
|
JP3969737B2
(ja)
|
1994-03-15 |
2007-09-05 |
エーザイ株式会社 |
イソプレニルトランスフェラーゼ阻害剤
|
HUT72440A
(en)
|
1994-03-31 |
1996-04-29 |
Bristol Myers Squibb Co |
Imidazole-containing inhibitors of farnesyl protein transferase and pharmaceutical compositions containing them
|
US5523430A
(en)
|
1994-04-14 |
1996-06-04 |
Bristol-Myers Squibb Company |
Protein farnesyl transferase inhibitors
|
US5510510A
(en)
|
1994-05-10 |
1996-04-23 |
Bristol-Meyers Squibb Company |
Inhibitors of farnesyl protein transferase
|
US5563255A
(en)
|
1994-05-31 |
1996-10-08 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US5532210A
(en)
|
1994-06-08 |
1996-07-02 |
E. I. Du Pont De Nemours And Company |
High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
|
EP0764149B1
(fr)
|
1994-06-10 |
1999-01-20 |
Aventis Pharma S.A. |
Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
|
US5571792A
(en)
|
1994-06-30 |
1996-11-05 |
Warner-Lambert Company |
Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
|
WO1996005529A1
(fr)
|
1994-08-09 |
1996-02-22 |
Micron Optics, Inc. |
Filtres de fabry-perot a fibres compense en temperature
|
DE69514367T2
(de)
|
1994-08-11 |
2000-07-27 |
Banyu Pharmaceutical Co., Ltd. |
Substituierte amidderivate
|
CA2155448A1
(fr)
|
1994-08-11 |
1996-02-12 |
Katerina Leftheris |
Inhibiteurs de la farnesyl-proteine-transferase
|
EP0805154A1
(fr)
|
1994-08-12 |
1997-11-05 |
Banyu Pharmaceutical Co., Ltd. |
Derive d'acide amique n,n-bisubstitue
|
DE4429506B4
(de)
|
1994-08-19 |
2007-09-13 |
Degussa Gmbh |
Verfahren zur Extraktion natürlicher Carotinoid-Farbstoffe
|
DE4429653C2
(de)
|
1994-08-20 |
1997-04-03 |
Anton Dr More |
Konverter und Verfahren zum Frischen von Metallschmelzen insbesondere von Roheisen zu Stahl
|
KR100389754B1
(ko)
|
1994-11-22 |
2003-10-17 |
코닌클리즈케 필립스 일렉트로닉스 엔.브이. |
반도체장치
|
AU3971295A
(en)
|
1994-12-09 |
1996-06-26 |
Warner-Lambert Company |
Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
|
EA000164B1
(ru)
|
1995-01-09 |
1998-10-29 |
Магла Интернэшнл Лтд. |
Состав для печати изображения на поверхности изделия из каучукового латекса, способ печати изображения и изделия из каучукового латекса
|
AU4915796A
(en)
|
1995-01-12 |
1996-07-31 |
University Of Pittsburgh |
Inhibitors of prenyl transferases
|
FR2729390A1
(fr)
|
1995-01-18 |
1996-07-19 |
Rhone Poulenc Rorer Sa |
Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
|
FR2730492B1
(fr)
|
1995-02-09 |
1997-03-14 |
Rhone Poulenc Rorer Sa |
Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
|
FR2730491B1
(fr)
|
1995-02-09 |
1997-03-14 |
Rhone Poulenc Rorer Sa |
Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
|
US5700806A
(en)
|
1995-03-24 |
1997-12-23 |
Schering Corporation |
Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
|
US5684013A
(en)
|
1995-03-24 |
1997-11-04 |
Schering Corporation |
Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
|
IL117580A0
(en)
|
1995-03-29 |
1996-07-23 |
Merck & Co Inc |
Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
|
US5891872A
(en)
|
1995-04-07 |
1999-04-06 |
Schering Corporation |
Tricyclic compounds
|
IL117798A
(en)
|
1995-04-07 |
2001-11-25 |
Schering Plough Corp |
Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
|
US5712280A
(en)
|
1995-04-07 |
1998-01-27 |
Schering Corporation |
Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
|
WO1996031501A1
(fr)
|
1995-04-07 |
1996-10-10 |
Schering Corporation |
Composes de piperazinyle et de piperidinyle carbonyles inhibant la transferase de proteine farnesyle
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5831115A
(en)
|
1995-04-21 |
1998-11-03 |
Abbott Laboratories |
Inhibitors of squalene synthase and protein farnesyltransferase
|
IL118101A0
(en)
|
1995-05-03 |
1996-09-12 |
Abbott Lab |
Inhibitors of farnesyltransferase
|
AU6034296A
(en)
|
1995-06-16 |
1997-01-15 |
Warner-Lambert Company |
Tricyclic inhibitors of protein farnesyltransferase
|
FR2736641B1
(fr)
|
1995-07-10 |
1997-08-22 |
Rhone Poulenc Rorer Sa |
Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
|
AT402617B
(de)
|
1995-07-11 |
1997-07-25 |
Datacon Schweitzer & Zeindl Gm |
Anlage zum automatisierten, hermetischen anlage zum automatisierten, hermetischen verschliessen von gehäusen verschliessen von gehäusen
|
FR2736638B1
(fr)
|
1995-07-12 |
1997-08-22 |
Rhone Poulenc Rorer Sa |
Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
|
CH690163A5
(fr)
|
1995-07-28 |
2000-05-31 |
Symphar Sa |
Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
|
WO1997017070A1
(fr)
|
1995-11-06 |
1997-05-15 |
University Of Pittsburgh |
Inhibiteurs de proteine-isoprenyle-transferases
|
DE59610712D1
(de)
|
1995-11-17 |
2003-10-16 |
Biotechnolog Forschung Gmbh |
Epothilonderivate, herstellung und verwendung
|
EP0862435A4
(fr)
|
1995-11-22 |
1999-02-03 |
Merck & Co Inc |
Inhibiteurs de la farnesyl-proteine transferase
|
EP1162201B1
(fr)
|
1995-12-08 |
2006-03-29 |
Janssen Pharmaceutica N.V. |
Dérivés de la ( imidazol-5-yl)méthyl-2-quinoléinone comme inhibiteurs de la protéine farnésyle transférase
|
NZ326035A
(en)
|
1995-12-22 |
2000-01-28 |
Schering Corp |
Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
|
WO1997026246A1
(fr)
|
1996-01-16 |
1997-07-24 |
Warner-Lambert Company |
Inhibiteurs substitues a base d'histidine agissant sur la farnesyltransferase proteinique
|
US6673927B2
(en)
|
1996-02-16 |
2004-01-06 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Farnesyl transferase inhibitors
|
JP2001519766A
(ja)
|
1996-04-03 |
2001-10-23 |
メルク エンド カンパニー インコーポレーテッド |
ファルネシルタンパク質トランスフェラーゼの阻害剤
|
NZ332712A
(en)
|
1996-05-22 |
2000-07-28 |
Warner Lambert Co |
Polypeptide inhibitors of protein farnesyl transferase
|
AU709409B2
(en)
|
1996-07-15 |
1999-08-26 |
Bristol-Myers Squibb Company |
Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
|
EP1386922B1
(fr)
|
1996-12-03 |
2012-04-11 |
Sloan-Kettering Institute For Cancer Research |
Synthèse d'épitholones, intermédiaires, analogues et leur utilisation
|
EP0951285A1
(fr)
|
1996-12-30 |
1999-10-27 |
Merck & Co., Inc. |
Inhibiteurs de farnesyl-proteine transferase
|
JP2002511054A
(ja)
|
1996-12-30 |
2002-04-09 |
メルク エンド カンパニー インコーポレーテッド |
ファルネシル蛋白トランスフェラーゼ阻害薬
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
DE69833755T2
(de)
|
1997-05-21 |
2006-12-28 |
Biovation Ltd. |
Verfahren zur herstellung von nicht-immunogenen proteinen
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
GB9818110D0
(en)
|
1998-08-19 |
1998-10-14 |
Weston Medical Ltd |
Needleless injectors and other devices
|
US6096002A
(en)
|
1998-11-18 |
2000-08-01 |
Bioject, Inc. |
NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
|
WO2000032634A1
(fr)
|
1998-12-01 |
2000-06-08 |
Protein Design Labs, Inc. |
Anticorps anti-interferon gamma humanises
|
NZ539776A
(en)
|
1999-01-15 |
2006-12-22 |
Genentech Inc |
Polypeptide variants with altered effector function
|
US20030035790A1
(en)
|
1999-01-15 |
2003-02-20 |
Shu-Hsia Chen |
Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
|
JP2002536968A
(ja)
|
1999-01-29 |
2002-11-05 |
イムクローン システムズ インコーポレイティド |
Kdrに特異的な抗体およびその使用
|
GB9904387D0
(en)
|
1999-02-25 |
1999-04-21 |
Pharmacia & Upjohn Spa |
Antitumour synergistic composition
|
WO2000061186A1
(fr)
|
1999-04-08 |
2000-10-19 |
Arch Development Corporation |
Utilisation d'anticorps anti-vegf pour accentuer le rayonnement lors d'une therapie anticancereuse
|
CA2704600C
(fr)
|
1999-04-09 |
2016-10-25 |
Kyowa Hakko Kirin Co., Ltd. |
Methode de production d'anticorps avec activite adcc accrue
|
US6794132B2
(en)
|
1999-10-02 |
2004-09-21 |
Biosite, Inc. |
Human antibodies
|
CA2388245C
(fr)
|
1999-10-19 |
2012-01-10 |
Tatsuya Ogawa |
L'utilisation de cellules de rat adaptess exemptes de serum pour produire de polypeptides heterologues
|
DE60114830T2
(de)
|
2000-06-28 |
2006-08-03 |
Glycofi, Inc. |
Verfahren zur herstellung modifizierter glycoproteine
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US6374470B1
(en)
|
2000-10-06 |
2002-04-23 |
Milliken & Company |
Face plate for spun-like textured yarn
|
WO2002083675A2
(fr)
|
2001-04-10 |
2002-10-24 |
Merck Sharp & Dohme Limited |
Inhibiteurs de l'activite de l'akt
|
WO2002083139A1
(fr)
|
2001-04-10 |
2002-10-24 |
Merck & Co., Inc. |
Inhibiteurs de l'activite d'akt
|
AU2002252614B2
(en)
|
2001-04-10 |
2006-09-14 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
WO2002083140A1
(fr)
|
2001-04-10 |
2002-10-24 |
Merck & Co., Inc. |
Inhibiteurs de l'activite d'akt
|
JP2004527531A
(ja)
|
2001-04-10 |
2004-09-09 |
メルク エンド カムパニー インコーポレーテッド |
癌を治療する方法
|
NZ592087A
(en)
|
2001-08-03 |
2012-11-30 |
Roche Glycart Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
US7514415B2
(en)
|
2002-08-01 |
2009-04-07 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
|
WO2003039460A2
(fr)
|
2001-11-07 |
2003-05-15 |
Merck & Co., Inc. |
Inhibiteurs de la kinesine mitotique
|
EP1481077B1
(fr)
|
2001-12-06 |
2009-11-04 |
Merck & Co., Inc. |
Inhibiteurs mitotiques de la kin sine
|
EP1463733B1
(fr)
|
2001-12-06 |
2007-09-05 |
Merck & Co., Inc. |
Inhibiteurs de kinesine mitotique
|
WO2003049678A2
(fr)
|
2001-12-06 |
2003-06-19 |
Merck & Co., Inc. |
Inhibiteurs mitotiques de la kinesine
|
US7262186B2
(en)
|
2001-12-06 |
2007-08-28 |
Merck & Co., Inc. |
Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor
|
AU2002364128B2
(en)
|
2001-12-06 |
2008-03-06 |
Merck Sharp & Dohme Corp. |
Mitotic kinesin inhibitors
|
DE60329990D1
(de)
|
2002-03-08 |
2009-12-24 |
Merck & Co Inc |
Mitotische kinesin-hemmer
|
AU2003226301A1
(en)
|
2002-04-08 |
2003-10-20 |
Merck And Co., Inc. |
Method of treating cancer
|
WO2003086403A1
(fr)
|
2002-04-08 |
2003-10-23 |
Merck & Co., Inc. |
Inhibiteurs de l'activite de akt
|
US7273869B2
(en)
|
2002-04-08 |
2007-09-25 |
Merck & Co., Inc. |
Inhibitors of Akt activity
|
WO2003086394A1
(fr)
|
2002-04-08 |
2003-10-23 |
Merck & Co., Inc. |
Inhibiteurs de l'activite akt
|
AU2003226250B2
(en)
|
2002-04-08 |
2007-08-16 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
AU2003226356A1
(en)
|
2002-04-12 |
2003-10-27 |
Ramot At Tel Aviv University Ltd. |
Prevention of brain inflammation as a result of induced autoimmune response
|
AU2003299517A1
(en)
|
2002-05-23 |
2004-05-25 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
AU2003231799A1
(en)
|
2002-05-23 |
2003-12-12 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
CA2486215A1
(fr)
|
2002-06-14 |
2003-12-24 |
Merck & Co., Inc. |
Inhibiteurs de kinesine mitotique
|
AU2003245453B2
(en)
|
2002-06-14 |
2008-08-14 |
Merck Sharp & Dohme Corp. |
Mitotic kinesin inhibitors
|
AU2003287057B2
(en)
|
2002-10-18 |
2008-08-21 |
Merck Sharp & Dohme Corp. |
Mitotic kinesin inhibitors
|
US20040102360A1
(en)
|
2002-10-30 |
2004-05-27 |
Barnett Stanley F. |
Combination therapy
|
ATE503483T1
(de)
|
2002-10-30 |
2011-04-15 |
Merck Sharp & Dohme |
Hemmer der akt aktivität
|
JP2006515171A
(ja)
|
2002-12-06 |
2006-05-25 |
ファルマシア コーポレイション |
ミトコンドリア膜に由来するミトneetポリペプチド、そのモジュレーター、及び該ミトneetポリペプチドの使用方法
|
CA2509212A1
(fr)
|
2002-12-20 |
2004-07-15 |
Merck & Co., Inc. |
Inhibiteurs de la kinesine mitotique
|
US7622489B2
(en)
|
2002-12-20 |
2009-11-24 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
CA2511538C
(fr)
|
2002-12-30 |
2013-11-26 |
3M Innovative Properties Company |
Complexes immunostimulants
|
ATE461179T1
(de)
|
2003-04-24 |
2010-04-15 |
Merck Sharp & Dohme |
Hemmer der akt aktivität
|
AU2004233835B2
(en)
|
2003-04-24 |
2010-02-25 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
WO2004096131A2
(fr)
|
2003-04-24 |
2004-11-11 |
Merck & Co., Inc. |
Inhibiteurs de l'activite akt
|
JP2006524254A
(ja)
|
2003-04-24 |
2006-10-26 |
メルク エンド カムパニー インコーポレーテッド |
Akt活性の阻害剤
|
US7410483B2
(en)
|
2003-05-23 |
2008-08-12 |
Novare Surgical Systems, Inc. |
Hand-actuated device for remote manipulation of a grasping tool
|
US7296030B2
(en)
|
2003-07-17 |
2007-11-13 |
At&T Corp. |
Method and apparatus for windowing in entropy encoding
|
KR100536215B1
(ko)
|
2003-08-05 |
2005-12-12 |
삼성에스디아이 주식회사 |
플라즈마 디스플레이 패널
|
CN100548296C
(zh)
|
2003-08-13 |
2009-10-14 |
默克公司 |
有丝分裂驱动蛋白抑制剂
|
EP1656133A4
(fr)
|
2003-08-15 |
2008-10-29 |
Merck & Co Inc |
Inhibiteurs de kinesine mitotique
|
PE20050730A1
(es)
|
2003-08-15 |
2005-09-20 |
Merck & Co Inc |
Derivados de 2,5-dihidropirrol 2,2-disustituidos como inhibidores de quinesinas mitoticas
|
WO2005019206A1
(fr)
|
2003-08-15 |
2005-03-03 |
Merck & Co., Inc. |
Inhibiteurs de la kinesine mitotique
|
JP2007502773A
(ja)
|
2003-08-15 |
2007-02-15 |
メルク エンド カムパニー インコーポレーテッド |
有糸分裂キネシン阻害薬
|
US7294640B2
(en)
|
2004-02-06 |
2007-11-13 |
Merck & Co., Inc. |
Mitotic kinesin inhibitors
|
EP1737843B1
(fr)
|
2004-04-09 |
2011-02-23 |
Merck Sharp & Dohme Corp. |
Inhibiteurs de l'activite d'akt
|
EP1737861A4
(fr)
|
2004-04-09 |
2010-04-28 |
Merck Sharp & Dohme |
Inhibiteurs de l'activite d'akt
|
EP1766396B1
(fr)
|
2004-06-07 |
2010-08-11 |
Ramot at Tel-Aviv University Ltd. |
Procede d'immunisation passive contre des maladies ou des troubles caracterise(e)s par agregation amyloide a risque diminue de neuroinflammation
|
AU2005269759A1
(en)
|
2004-07-21 |
2006-02-09 |
Glycofi, Inc. |
Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
|
DK3339445T3
(da)
|
2006-09-08 |
2020-10-19 |
Abbvie Bahamas Ltd |
Interleukin -13 bindende proteiner
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
EP2090320A1
(fr)
|
2008-02-15 |
2009-08-19 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Ligands du marqueur CD27 de surface de cellule tueuse naturelle (NK) et ses utilisations thérapeutiques
|
AU2009267294B2
(en)
|
2008-06-30 |
2014-06-26 |
Kyowa Kirin Co., Ltd. |
Anti-CD27 antibody
|
EP2445530B1
(fr)
|
2009-06-24 |
2016-09-07 |
The Feinstein Institute for Medical Research |
Procédé pour traiter la leucémie lymphocytaire chronique
|
KR101898739B1
(ko)
*
|
2009-11-04 |
2018-09-13 |
머크 샤프 앤드 돔 코포레이션 |
조작된 항-tslp 항체
|
CA2785964C
(fr)
|
2009-12-29 |
2021-03-30 |
Kyowa Hakko Kirin Co., Ltd. |
Anticorps anti-cd27
|
NZ602892A
(en)
|
2010-04-13 |
2014-08-29 |
Celldex Therapeutics Inc |
Antibodies that bind human cd27 and uses thereof
|
AU2013203270B2
(en)
|
2010-04-13 |
2016-05-19 |
Celldex Therapeutics Inc. |
Antibodies that bind human CD27 and uses thereof
|
JP6023706B2
(ja)
|
2010-07-09 |
2016-11-09 |
アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップAduro Biotech Holdings, Europe B.V. |
Cd27に対するアゴニスト抗体
|
WO2012019041A2
(fr)
|
2010-08-04 |
2012-02-09 |
Duke University |
Lymphocytes b régulateurs et leurs utilisations
|
CA2812416A1
(fr)
|
2010-09-22 |
2012-03-29 |
The Feinstein Institute For Medical Research |
Cellules b1 humaines et leurs utilisations
|
WO2012177624A2
(fr)
|
2011-06-21 |
2012-12-27 |
The Johns Hopkins University |
Rayonnement focalisé pour améliorer les thérapies basées sur l'immunité contre les néoplasmes
|
UA118332C2
(uk)
|
2011-09-22 |
2019-01-10 |
Емджен Інк. |
Білок, що зв'язує антиген cd27l
|
BR112014022812A2
(pt)
|
2012-03-15 |
2017-07-18 |
Janssen Biotech Inc |
anticorpos anti-cd27 humanos, métodos e usos
|
CA2890438C
(fr)
*
|
2012-11-13 |
2022-10-18 |
Biontech Ag |
Agents de traitement de maladies cancereuses exprimant claudine
|
US9725494B2
(en)
|
2013-05-17 |
2017-08-08 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Soluble CD27 (sCD27) and the use thereof
|
RU2016107426A
(ru)
|
2013-08-02 |
2017-09-07 |
Адуро Байотек Холдингс, Юроуп Б.В. |
Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
|
CA2943167A1
(fr)
|
2014-03-24 |
2015-10-01 |
University Of Southampton |
Anticorps modifies contenant des domaines d'igg2 modifies conferant des proprietes agonistes ou antagonistes, et utilisation de ces derniers
|
WO2016145085A2
(fr)
|
2015-03-09 |
2016-09-15 |
Celldex Therapeutics, Inc. |
Agonistes cd27
|
JOP20190055A1
(ar)
*
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|